(Total Views: 430)
Posted On: 09/19/2025 1:47:02 PM
Post# of 157138
This is a bit astounding. In March of this year Dr. Jay (in his letter to shareholders) commented:
Yet somehow, even though the company itself applied to have leronlimab included in the next round of studies, RECOVER has responded to Ganesha and asked him, rather than the company itself, if he has access to results from the company's Long Covid studies. Maybe Cytodyn screwed up its application, or, more likely, RECOVER has mismanaged its application.
Ganesha, I think we should inform CYDY management about this. I can copy your post and send it to Dr. Jay, or you can. Would you like to do it, or should I?
Thanks for your work in submitting Leron to RECOVER, meanwhile. I think Plotinus did the same.
Quote:
As previously announced, CytoDyn applied to the NIH/RECOVER-TLC group for the inclusion of leronlimab in their next round of Long Covid treatment studies. The shifting policy landscape in the United States has created some uncertainty around government-sponsored funding of research, but we have been informed by a member of the RECOVER team that their review process has resumed, and we expect a decision soon.
Yet somehow, even though the company itself applied to have leronlimab included in the next round of studies, RECOVER has responded to Ganesha and asked him, rather than the company itself, if he has access to results from the company's Long Covid studies. Maybe Cytodyn screwed up its application, or, more likely, RECOVER has mismanaged its application.
Ganesha, I think we should inform CYDY management about this. I can copy your post and send it to Dr. Jay, or you can. Would you like to do it, or should I?
Thanks for your work in submitting Leron to RECOVER, meanwhile. I think Plotinus did the same.
(11)
(0)
